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Unusual susceptibility to mycobacterial infections can be
caused by deleterious mutations in genes that encode the
interferon-γ receptor 1 chain. Such mutations hamper the ac-
tivation of macrophages by a type 1 immune response and result
in enhanced survival of intracellular pathogens. We here re-
port two patients with unusual mycobacterial infections, both
diagnosed with homozygous deleterious interferon-γ receptor
1 gene mutations. Patient 1 became ill after Bacillus Calmette–
Gue´rin vaccination at the age of 9 months and died at the age
of 18 months. She carried a homozygous C71Y mutation in the
extracellular part of the mature interferon-γ receptor 1 protein,
resulting in the lack of detectable protein expression and absence
of interferon-γ dependent signaling. Patient 2 became ill at the
age of 3 years, is still alive at 19 years of age, and has suffered
from five successive infection episodes with atypical mycobac-
teria. A homozygous splice-site mutation in intron 3 was iden-
tified, resulting in the deletion of exon 3 at the mRNA level and
consequently a truncated interferon-γ receptor 1 protein with
absence of the transmembrane domain. Protein expression and
interferon-γ dependent signaling were not detectable.
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INTRODUCTION
The interferon-γ receptor (IFN-γ R) consists of two
chains, the ligand-binding chain (IFN-γ R1), and an ac-
cessory chain (IFN-γ R2), which is required for signal
transduction. The IFN-γ R is expressed on most nucleated
cells. Upon binding of IFN-γ , two IFN-γ R1 chains will
dimerize and subsequently associate with two IFN-γ R2
chains to form a tetrameric complex. The intracellular do-
mains of IFN-γ R1 and 2 are constitutively bound to Janus
kinases (JAK)-1 and -2, respectively, that upon activation
will phosphorylate a Tyrosine at amino acid (aa) position
440 (Y440) in the intracellular domain of IFN-γ R1. This
phosphorylation generates a docking site for signal trans-
ducer and activator of transcription (STAT) 1α, which, in
turn, becomes phosphorylated. Phosphorylated STAT1α
homodimers will translocate to the nucleus and bind to
specific sequences in the promoter region of early IFN-γ
inducible genes (1–4). Furthermore, IFN-γ can augment
the IL-12 production by macrophages, which will stimu-
late T-helper 1 (Th1) and NK cells to produce IFN-γ (4).
Intracellular signaling from the IFN-γ R is required for
killing of intracellular pathogens, such as mycobacteria,
by macrophages (5, 6). Mutations in the genes encoding
the IFN-γ R1 or 2 chains (7–9), the β1 chain of the IL-12R
(10, 11), IL-12p40 (12), or STAT-1 (13), have been shown
to result in enhanced susceptibility to mycobacterial in-
fections (14, 15).
Mutations in the IFNGR1 gene can cause either com-
plete or partial signaling defects, resulting in two dis-
tinct phenotypes (16–18). First, patients suffering from
a complete signaling defect generally present with dif-
fuse and poorly differentiated, lepromatoid-like granulo-
mas with many bacilli, have a poor prognosis, and can
only be treated by bone marrow transplantation (BMT).
Complete signaling defects can be divided into two
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Table I. Atypical Mycobacteria Cultured and Subsequent Treatment
Patient Disease episode Age at biopsy (years)
Culture result from
lymph-node biopsy Treatment Cured
1 (female) — 1 M. avium INH/ANS/ETH/CLO/MYA No
2 (male) 1 4 M. gordonae RIF/CIP/CLO Yes
2 6 M. peregrinum RIB/CIP/CLA/CLO Yes
3 16 M. mageritense OFL/DOX/BAC Yes
4 17 M. szulgai MER/OFL Yes
5 18 M. mageritense MER/CEF Yes
Note. ANS, Ansamycin; BAC, Trimethoprim/sulphametoxazol; CEF, Cefoxitin; CIP, Ciprofloxacin; CLA, Clarithromycin; CLO, Clofazimin; DOX,
Doxycyclin; ETH, Ethionamid; INH, Isoniazid; MER, Meropenem; MYA, Ethambutol; OFL, Ofloxacin; RIB, Rifabutin; RIF, Rifampicin.
subgroups, distinguishable by the absence or the presence
of IFN-γ R1 protein expression on the surface membrane
(SmIFN-γ R1). In cases with complete signaling defects
but with the presence of SmIFN-γ R1, the causative de-
fect is in the IFN-γ binding capacity of the IFN-γ R (18).
Both subgroups show an autosomal recessive (AR) in-
heritance. Several reports concerning patients with com-
plete IFN-γ R1 deficiency have been published before
(19–27).
In contrast to patients with complete IFN-γ R1 signal-
ing defects, patients suffering from a partial IFN-γ R1 sig-
naling defect generally present with well-circumscribed
and well-differentiated tuberculoid granulomas with few
visible acid-fast rods. They have a better prognosis,
and may respond to treatment with IFN-γ or antimy-
cobacterial chemotherapy. Partial signaling defects caused
by mutations in the IFNGR1 gene may inherit either
as an AR trait or as an autosomal dominant (AD)
trait. The AR mutations generally lead to partially
perturbed IFN-γ R signaling (28), The AD mutations
lead to an intracellular truncated form of the IFN-γ R1
chain, which still can bind IFN-γ , but lacks intracellu-
lar signal-transducing and recycling domains, and fails to
be internalized from the surface membrane (29). Thus,
the AD form displays a dominant negative, inhibitory
phenotype.
Here, we present the clinical, functional, and genetic
analyses of two patients with complete IFN-γ R1 defi-
ciency.
PATIENTS
Patient 1 (female) had consanguineous parents of Pak-
istani origin. In this family, four out of eight children
died, two after BCG vaccination. Her disease course
was described before (30). In short, she became sick
after BCG vaccination at the age of 9 months. Al-
though a systemic BCG-itis was suspected, M. avium
was cultured from peripheral blood (PB), stomach, liver,
lymph node and bone. This microorganism was resistant
to Isoniazid, Rifampicin, Ethambutol and Streptomycin
(Table I). Sensitivity to other antimicrobial agents was
not performed. Serum IgG and IgM titers against cy-
tomegalovirus (CMV), Epstein–Barr virus (EBV), and
herpes simplex virus (HSV) were negative. Serum IgG
levels against HIV, Q-fever, and Toxoplasma were nega-
tive. Despite antituberculous drugs and short-term IFN-γ ,
she died at the age of 18 months.
Patient 2 (male) is the only child of Dutch, non-
consanguineous parents and became sick at the age of
3 years. He did not receive a BCG vaccination. M.
gordonae, M. peregrinum, M. mageritense, M. szulgai,
and M. mageritense were cultured from lymph-node biop-
sies during five consecutive independent disease episodes
(Table I). These disease episodes started with malaise
and weight loss, which evolved into fever and specific
complaints like lymphadenopathy or arthritis (episode 4)
after some weeks. During fevers, the laboratory results
showed elevated inflammatory parameters like ESR and
CRP in combination with leukocytosis. Ultrasound of the
enlarged lymph nodes revealed central necrosis with pus
that yielded a mycobacterial species after puncture and
culture. After starting appropriate treatment, he responded
within 2 weeks. For each disease episode he received an-
timicrobial therapy (Table I) varying from 6 to 9 months,
depending on the speed of lymph-node resolution. At the
age of 19 years, he was transferred in a good clinical con-
dition to an infectious disease specialist for adults. At that
time, he was off therapy. Serum IgG titers against different
agents associated with lymphadenopathy were negative.
Varicella Zoster virus (VZV) serology was compatible
with a positive history for VZV infection in the past.
Salmonella serology was not performed.
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All cell samples were obtained according to the in-
formed consent guidelines of the Medical Ethics Com-
mittee of the Erasmus MC.
MATERIALS AND METHODS
IFN-γ R1 Protein Expression
Granulocytes and mononuclear cells were isolated from
PB by Ficoll-Paque (density: 1.077 g/mL; Pharmacia,
Uppsala, Sweden) density centrifugation. Either periph-
eral blood mononuclear cells (PBMC) stimulated for 3
days with PHA at a final concentration of 2 µg/mL, or
PHA-stimulated T-cell lines, from patients and controls
were stained for 30 min at 4◦C with specific MAb (clones
from Pharmingen, San Jose, CA, or Genzyme, Cambridge,
MA) or the respective isotype controls, washed, fixed, and
analyzed by FACSCalibur (Becton Dickinson, San Jose,
CA) for SmIFN-γ R1 protein (CD119) expression (31).
IFN-γ Responsiveness of Cells from Patient 2
The response of cells from patient 2 to IFN-γ was
monitored by the IFN-γ mediated upregulation of
CD64 on the PBMC-derived monocytic cell fraction as
determined by flow cytometry using a CD64-specific
MAb (Pharmingen).
The response of patient 2 and control cells to IFN-γ was
also analyzed by measuring the enhancement of IL-12 and
TNF-α secretion and by the inhibition of IL-10 secretion
after stimulation of whole blood cells with LPS (from E.
coli, Sigma) at a final concentration of 100 ng/mL. Briefly,
200 µL of a whole blood cell suspension, that was col-
lected in endotoxin-free tubes and five times diluted in
Iscove’s Modified Dulbecco’s Medium (Bio-Whittaker,
Verviers, Belgium), was incubated with LPS in the pres-
ence or absence of up to 1000 U IFN-γ (Boehringer
Ingelheim). After overnight incubation, IL-12p40, TNF-
α, and IL-10 were measured in the collected supernatant
of three wells by ELISA (R&D Systems) (31).
Furthermore, polymorphonuclear cells (PMN) from pa-
tient 2 were stimulated in vitro with IFN-γ and analyzed
for phosphorylation of STAT-1, binding of STAT-1 to
DNA, and intracellular killing of Toxoplasma gondii and
Salmonella typhimurium.
STAT-1 DNA Binding Assay
After stimulation of PMN with IFN-γ (10, 100, 1000,
and 10,000 U) for 20 min, cellular extracts were prepared.
Protein-DNA complexes were detected by electrophoretic
mobility shift assay (EMSA). Ten micrograms of extract
were incubated for 30 minutes at 4◦C in a 10 mM Hepes
buffer containing 60 mM KCl, 1 mM EDTA, 1 mM DTT,
10 mM Na3PO4, 10% glycerol, 1 µg poly(dI-dC), 0.5 µg
sonicated herring sperm ssDNA, and 1 ng of 32P radio-
labeled dsDNA probe corresponding to the IFN-γ re-
sponse region. Supershift experiments were performed
by incubating formed complexes with STAT-1 specific
antibody E23 (Santa Cruz Biotechnology, Santa Cruz,
CA) for 60 min on ice. Samples were separated by elec-
trophoresis on a 6% nondenaturing polyacrylamide gel.
Gels were fixed with 10% methanol and 10% acetic acid,
dried onto Whatmann 3M paper, and exposed to an X-ray
film (31).
DNA and RNA Extraction and Reverse
Transcriptase Reaction
DNA was extracted from granulocytes using the
QIAamp Blood kit (Qiagen, Chatsworth, CA, USA)
(32). Total RNA was isolated from PBMC according to
the method of Chomczynski using RNAzol B (Tel-Test,
Friendswood, TX, USA) (33). cDNA was prepared from
mRNA as described before, using random hexamers and
Superscript reverse transcriptase (34).
PCR Amplification of (c)DNA
PCR was performed as described previously (34). In
each 100 µL PCR reaction, 0.1 µg (c)DNA, 20 pmol of
forward and reverse oligonucleotides, and 1 U AmpliTaq
gold polymerase (Applied Biosystems, Foster City, CA,
USA) were used. PCR conditions were 7 min at 95◦C,
followed by 30 s at 94◦C, 90 s at 57–60◦C, 2 min at 72◦C
for 40 cycles, followed by a final extension step (10 min
at 72◦C).
The sequences of the oligonucleotides used for PCR
amplification of the IFNGR1 gene and mRNA were based
on human sequences with Genbank accession numbers
AL050337 and J03143 (35), respectively, and were de-
signed with the OLIGO 6 program (Dr. W. Rychlik,
Molecular Biology Insights, Cascade, CO) (36). Primer
sequences will be made available on request to interested
readers.
Fluorescent Sequencing Reaction and Analysis
PCR products were first purified with the QIAquick
PCR purification kit (Qiagen), and were subsequently
used for sequencing with 5 µL big dye terminator
mix (Applied Biosystems), using 3.3 pmol sequencing
primers. The sequencing primers were positioned in the
IFNGR1 introns sufficiently upstream and downstream
of the exon–intron borders to evaluate the splice-site
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sequences. All sequencing was performed as described
before (37), and run on an ABI Prism 377 fluorescent
sequencer (Applied Biosystems).
RESULTS
Flow Cytometric Analysis of IFN-γ R1 Expression
Relatively frequently, the syndrome of high suscepti-
bility to unusual mycobacterial infections has been asso-
ciated with causative, deleterious genetic mutations in the
IFNGR1 gene (16–18). Therefore, we screened our two
patients suffering from unusual mycobacterial infections
for the expression of IFN-γ R1 proteins (CD119), using
two different MAb’s. As shown in Fig. 1, we could not find
any detectable levels of SmIFN-γ R1 protein expression
on PHA blasts at day 3 after stimulation, neither on cells
from patient 1, nor on cells from patient 2.
Functional Analysis of IFN-γ Mediated Responses
In order to assess the capacity of cells from patient 2
to respond to IFN-γ , we monitored by flow cytometry
the upregulation of CD64 (Fcγ R1) on monocytic cells
from patient 2 and controls in response to increasing
doses of IFN-γ . The basal CD64 expression was nor-
mal both in the control cells as well as in the cells from
patient 2. In response to IFN-γ , control cells showed
normal upregulation of CD64. However, no CD64 up-
regulation was found in cells from patient 2 (data not
shown).
Additionally, for patient 2, we performed an in vitro
stimulation of whole blood cells with LPS in the pres-
ence or absence of recombinant human IFN-γ (Fig. 2).
As read-out, we measured the secreted levels of IL-12p40
or IL-10 by ELISA, which should be increased and de-
creased, respectively, if the IFN-γ R signaling cascade
would still be intact. In accordance with the absence of
detectable SmIFN-γ R1 protein expression on patient cells
and supporting the lack of CD64 upregulating-capacity,
cells from patient 2 did not show an augmented IL-12p40
secretion nor an inhibited IL-10 secretion in response to
IFN-γ (Fig. 2). We also failed to detect an IFN-γ mediated
upregulation of TNF-α production in cells from patient 2
(data not shown).
Finally, after stimulation of PMN from patient 2 with
IFN-γ , we were not able to detect STAT-1 phosphoryla-
tion, binding of STAT-1 to DNA, or intracellular killing of
Toxoplasma gondii or Salmonella typhimurium (data not
shown).
Fig. 1. Flow cytometric analysis of IFN-γ R1 (CD119) protein expres-
sion on PHA blasts. Patient or control cells were stained with two dif-
ferent IFN-γ R1 specific, nonblocking MAb’s (clones from Pharmingen
(A) and Genzyme (B)), and analyzed by flow cytometry. Both controls,
but neither of the two patients, showed detectable levels of IFN-γ R1
proteins at their cell surface. Control 2 was the mother of patient 2.
Shown are histograms of the fluorescent signal with isotype controls
depicted by thin lines and specific staining depicted by bold lines.
Characterization of IFNGR1 Gene Mutations
Since the aforementioned phenotypic and functional
analyses indicated that both patient 1 and patient 2 suf-
fered from a complete IFN-γ R1 signaling defect due to
the absence of detectable SmIFN-γ R1 protein expression,
we aimed at the identification of mutations in the IFNGR1
gene. Sequencing of PCR products from patient 1 showed
a homozygous G to A substitution at nucleotide position
54 in exon 3 of the IFNGR1 gene (r.254G > A). This
mutation was confirmed in IFNGR1-mRNA and results
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Fig. 2. Secretion of IL-12p40 and IL-10 after stimulation with
IFN-γ . Whole blood cells from controls or patient 2 were tested for
IFN-γ mediated enhancement of IL-12p40 secretion or IFN-γ mediated
inhibition of IL-10 secretion upon stimulation by LPS. A. Both a healthy
control and the mother of patient 2, but not patient 2 himself, showed a
concentration-dependent increase in the level of secreted IL-12p40 upon
LPS stimulation in the presence of IFN-γ . B. In contrast to a healthy
control, patient 2 showed no concentration-dependent decrease in the
amount of secreted IL-10 in the presence of IFN-γ .
in a C71Y aa substitution of the mature protein. The fa-
ther and mother of this patient as well as her sister were
heterozygous carriers without clinical manifestations. Her
brother was homozygous for the wild-type IFNGR1 gene.
Sequencing of PCR products from patient 2 showed
a homozygous G to T substitution at nucleotide position
1 in intron 3 of the IFNGR1 gene (r.373 + 1G > T).
This splice-site mutation leads to the deletion of 173 nu-
cleotides starting at position 249 of the IFNGR1-mRNA
(35), which corresponds to the complete absence of
exon 3. This leads to a frame shift and a premature stop
at codon 73 of the mature protein, with only part of the
extracellular domain of the IFN-γ R1 protein translated.
Fig. 3. RT-PCR products of IFNGR1-mRNA on agarose gel. The ho-
mozygous splice-site mutation in patient 2 leads to a complete deletion
of exon 3 at the mRNA level. PBMC of his parents expressed both the
wt and the mutated mRNA. Their carrier status was confirmed at the
genomic DNA level.
Both nonconsanguineous parents were heterozygous for
this mutation, as shown at the mRNA (Fig. 3), and the
DNA level. This same mutation has been described before
in a compound heterozygous child (38).
DISCUSSION
Signaling defects resulting from deleterious mutations
in the IFNGR1 gene can be subdivided into four groups,
based on the severity of the signaling defect, the mode
of inheritance, absence or presence of remaining SmIFN-
γ R1 proteins, and IFN-γ binding capacity (16–18). Pa-
tients with a complete signaling defect generally have a
poor prognosis, while patients with a partial signaling
defect generally have a better prognosis. In this study, two
patients with complete IFN-γ R1 signaling defects were
carefully analyzed, both at the molecular, biochemical,
and cellular levels.
Patient 1 became ill after BCG vaccination at the age
of 9 months and died at the age of 18 months. She had a
homozygous C71Y mutation in the mature protein. The
Cysteine at aa position 71 forms an intrachain disulfide
bridge with the Cysteine at aa position 63 (39).
We could not detect any IFN-γ R1 protein expression on
PHA blasts from patient 1 (Fig. 1). However, as we used
only two MAb’s, the failure to detect protein expression
could also be caused by changed protein conformation.
This might lead to disappearance of epitopes normally
recognized by our MAb. This hypothesis would be in
line with the report of an IFN-γ R1 C63Y mutation in
a patient with mycobacterial infections where IFN-γ R1
is expressed (18). Another possibility is that the C71Y-
mutated IFN-γ R1 chain becomes unstable resulting in
the absence of protein expression.
It has been shown before that site-directed mutagenesis
of Cysteine at position 71 and/or position 63 to Serine
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completely abolished IFN-γ binding (39). Also the
IFN-γ R1 C63Y mutation completely abolished IFN-γ
binding (18). Based on these observations, we hypothe-
size that the severe clinical phenotype and the laboratory
data of patient 1 with the C71Y mutation could be the
result of a complete signaling defect.
Although patient 2 showed a relatively mild clini-
cal course, we could neither detect IFN-γ R1 protein
expression nor IFN-γ mediated responses in this pa-
tient, indicative for a complete IFN-γ R1 signaling defect
(Figs. 1 and 2). The absence of upregulation in CD64 ex-
pression and IL-12p40 production as well as the absence
of downregulation in IL-10 production (Fig. 2) in response
to IFN-γ , corresponds to a defect in the signaling cascade
via the IFN-γ R.
Indeed, molecular analysis of the IFNGR1 gene re-
vealed the presence of a homozygous splice-site mutation
in intron 3, resulting in the absence of exon 3 at the mRNA
level. The consequent premature truncation of the protein
results in the absence of a large part of the extracellular
domain, the complete transmembrane and all intracellu-
lar domains. This splice-site mutation has been described
before in a compound heterozygous patient (38). How-
ever, splice-site mutations may allow low levels of nor-
mal splicing, resulting in the presence of wild-type (wt)
mRNA (40). Such a mechanism could putatively explain
the relatively mild clinical course in patient 2. We used
real-time quantitative (RQ)-PCR with specific primers for
wt transcripts (40), which detected wt IFNGR1-mRNA in
patient 2 after 36 cycles, corresponding to mRNA levels
that were 1 × 104 times lower than the levels detected
in a myeloid control cell line (data not shown). Such very
low levels of wt IFNGR1 transcripts are most likely not
sufficient for explaining the relatively mild clinical course
in patient 2.
The oldest patient reported so far with a complete IFN-
γ R1 signaling defect is patient 20q described by Dorman
et al. (15). In general, patients with a complete IFN-γ R1
signaling defect have a poor prognosis and can only be
treated by bone marrow transplantation (BMT). It might
be that other factors, such as genetic background or access
to specialized pediatric treatment, explain the difference
in clinical outcome between these patients.
In conclusion, our report confirms that deleterious
IFNGR1 mutations result in increased susceptibility to
mycobacterial infections.
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